Hofseth BioCare ASA (HBC) has appointed Ole Arne Eiksund as new VP Global Sales. Eiksund has held several positions in the last 20 years at GlaxoSmithKline and GE Healthcare and comes from the position as Commercial Director at GSK. He has extensive international sales experience and also holds an Executive MBA from Hult International Business School. Eiksund joins HBC by the end of August 2014.
In addition, HBC this summer has recruited Karen Marie Måseide Hovland as project manager, Kai Morten Thuen as marketing manager and Matt Mixter as general manager for HBCs US office.
For further information, please contact:
Jon Olav Ødegård , CEO of Hofseth BioCare ASA
Tel : +47 936 32 966
E - mail: joo@h-bc.no
Jon Olav Ødegård , CEO of Hofseth BioCare ASA
Tel : +47 936 32 966
E - mail: joo@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.